MARKETSnap
  • Gainers &
    Losers
  • Most Active &
    More
  • 52-Week
    High/Low
  • P/E
    Ratios
    • Large Caps
    • Absolute
    • Total Market PE
  • Stocks
    Performance
    • Large Caps
    • Absolute
  • Industries
    Performance
    • Industry
    • Sector
  • Dividends
  • 📅 Calendar
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 🔧 Tools
    • 💰 Intrinsic Value Calculator
    • 📈 Compounding Calculator
    • 🤖 Stock Pick Screener
  • More
    • Charts
    • Investment Compounding Calculator
    • Commodities
    • Currencies
    • Economic Indicators
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
ALVO stock logo

ALVO

Alvotech

$4.83
-0.08
 (-1.55%)
Exchange:  NASDAQ
Market Cap:  1.635B
Shares Outstanding:  243.65M
Delayed data
Calculate ALVO Intrinsic Value
5-year outlook →
Overview
Earnings
Financials
Valuation
Chart

About The Company

Sector:  Healthcare
Industry:  Drug Manufacturers – Specialty & Generic
   
CEO:  Lisa Graver
Full Time Employees:  1279
Address: 
9, Rue de Bitbourg
Luxembourg
LU
1273
LU
Website:  https://www.alvotech.com
Alvotech, along with its various subsidiaries, is dedicated to the global development and manufacturing of biosimilar pharmaceuticals. Its product offerings span key therapeutic categories, encompassing autoimmune conditions, eye disorders, bone diseases, and cancer. A flagship program for the company is AVT02, a high-concentration biosimilar equivalent to Humira. This candidate is designed to address a range of inflammatory illnesses, including rheumatoid arthritis, psoriatic arthritis, Crohn’s disease, ulcerative colitis, and plaque psoriasis. Similarly, AVT04 is a biosimilar version of Stelara, targeting inflammatory conditions such as psoriatic arthritis, Crohn’s disease, ulcerative colitis, and plaque psoriasis. For ophthalmic conditions, AVT06 serves as a biosimilar to Eylea, intended for the treatment of age-related macular degeneration, macular edema, and diabetic retinopathy. Currently in preclinical stages, AVT03 is a biosimilar to Xgeva and Prolia, with the goal of preventing bone fractures, alleviating spinal cord compression, reducing the necessity for radiation or bone surgery in certain cancer patients, and both preventing bone loss and increasing bone density. Additionally, Alvotech’s pipeline features AVT05, an early-stage biosimilar for Simponi and Simponi Aria, which is being developed for various inflammatory conditions like rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. Other promising candidates include AVT16, an immunology biosimilar; AVT23, a late-stage biosimilar to Xolair, aimed at treating nasal polyps; and AVT33, an oncology biosimilar. Established in 2013, Alvotech maintains its primary corporate headquarters in Reykjavik, Iceland.

Click to read more…

Revenue Segmentation

MARKETSnap
MARKETSnap

Log in to continue

Log in to see the complete revenue and geographic breakdown.

Login — it's free

EPS

Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.

Log in to continue

Log in for the full EPS chart and links to analyst estimates.

Login — it's free
View full analyst estimates

Earnings Call

Full text

Earnings transcript

Read the complete earnings call transcript.

AI summary

Key takeaways

Short, structured highlights from the call so you can focus on what matters.

2026/05/07 — Q1 quarter 2026

Log in to continue

Log in to read the full transcript and AI-generated earnings summaries.

Login — it's free
Income Statement
Balance Sheet
Cash Flow Statement
Analyst Estimates

Income Statement

Year202320242025
Revenue91,434489,682586,321
Gross Profit-69,422304,373350,763
EBITDA-493,672-32,275323,389
Operating Income-354,86069,64478,207
Net Income-551,731-231,86427,919

Log in to continue

Log in to see the income statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Balance Sheet

Year202320242025
Total Assets950,0901,221,4001,487,099
Total Liabilities1,882,5831,634,1711,771,586
Total Stockholders Equity-932,493-412,771-284,487
Total Debt1,075,4741,190,2361,449,145
Cash and Cash Equivalents11,15751,428172,359

Log in to continue

Log in to see the balance sheet and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Cash Flow Statement

Year202320242025
Operating Cash Flow-312,185-236,843-50,197
Capital Expenditure-46,473-57,000-64,470
Free Cash Flow-358,658-293,843-114,667
Net Income-551,731-231,86427,919
Net Change in Cash-55,27040,271120,931

Log in to continue

Log in to see the cash flow statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Analyst Estimates

Fiscal Year2030Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (Low)1,200,764.632Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (High)1,447,417.626Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (Avg)1,303,666.667Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (Low)-580,327.567Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (High)-481,434.525Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (Avg)-522,692.063Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (Low)309,836.687Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (High)394,757.910Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (Avg)345,265.898Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (Low)1,348,824.937Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (High)1,625,891.483Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (Avg)1,464,415.309Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (Avg)1.240Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (High)1.410Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (Low)1.110Research AccessResearch AccessResearch AccessResearch Access
Number of Analysts (Estimated Revenue)2Research AccessResearch AccessResearch AccessResearch Access
Number of Analysts (Estimated EPS)1Research AccessResearch AccessResearch AccessResearch Access

Log in to continue

Log in and subscribe to Full Access to see up to 5 years of analyst estimates.

Login — it's free

(* All numbers are in thousands)

Current Key Metrics

?Revenue
 (TTM)
: 
489.682M  ?P/S
 (TTM)
: 
3.05
?Net Income
 (TTM)
: 
-231864000  ?P/E
 (TTM)
: 
-7.58
?Enterprise Value
 (TTM)
: 
2.807B  ?EV/FCF
 (TTM)
: 
-9.35
?Dividend Yield
 (TTM)
: 
0%  ?Payout Ratio
 (TTM)
: 
0%
?ROE
 (TTM)
: 
76.83%  ?ROIC
 (TTM)
: 
3.61%
?Net Debt
 (TTM)
: 
1.139B  ?Debt/Equity
 (TTM)
: 
-7.58
?P/B
 (TTM)
: 
-8.26  ?Current Ratio
 (TTM)
: 
1.65

Log in to continue

Log in to see all key valuation metrics and ratios for this symbol.

Login — it's free

Forward P/E Ratios

?

Forward P/E (Avg EPS estimate) — log in with Research Access for high/low estimates and the interactive table.

Forward P/E 1YResearch AccessResearch AccessResearch AccessResearch Access
11.79Research AccessResearch AccessResearch AccessResearch Access

Log in to continue

Log in with Full Access for forward P/E high/low estimates and the full multi-year table.

Login — it's free

SWOT Analysis

🔒 You are currently logged out

Login

It's free

At what price to buy it? -
Intrinsic Value Calculator

This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.

[intrinsic_calculator]

Common questions about ALVO valuation

Is Alvotech (ALVO) overvalued or undervalued right now?

MARKETSnap estimates intrinsic value for Alvotech (ALVO) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.

Is ALVO a buy, hold, or sell for long-term investors?

MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether ALVO trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.

What is ALVO’s P/E ratio?

You can see ALVO’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.

How is intrinsic value calculated for ALVO?

MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.

Is ALVO a good long-term investment?

Whether ALVO fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.

ALVO

1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.

Daily snapshot

-1.55
MARKETSnap

Trading Metrics:

Open: 4.94   Previous Close: 4.91
Day Low: 4.81   Day High: 4.98
Year Low: 2.94   Year High: 9.25
Price Avg 50: 3.73   Price Avg 200: 4.16
Volume: 608971   Average Volume: 753972

Log in to continue

Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.

Login — it's free
See in Nexus

Relevant news

Alvotech Announces Licensing and Commercialization Agreement with Lotus Pharmaceutical for proposed biosimilars to durvalumab and emicizumab in the U.S. and Selected Asian Markets
21-08-2026 09:00
Alvotech Announces Licensing and Commercialization Agreement with Lotus Pharmaceutical for proposed biosimilars to durvalumab and emicizumab in the U.S. and Selected Asian Markets
Alvotech: Reiterate Hold On AVT05/AVT06 BLA Resubmissions And Upcoming Catalysts
20-08-2026 14:21
Alvotech: Reiterate Hold On AVT05/AVT06 BLA Resubmissions And Upcoming Catalysts
Alvotech Q2 Earnings Call Highlights
20-08-2026 10:03
Alvotech Q2 Earnings Call Highlights
Alvotech Announces Financial Results for the First Half of 2026 and Provides a Business Update
19-08-2026 16:30
Alvotech Announces Financial Results for the First Half of 2026 and Provides a Business Update
Transactions of Managers and Closely Associated Persons
10-06-2026 16:30
Transactions of Managers and Closely Associated Persons
Alvotech further strengthens liquidity by securing term loan facility of $75 million
01-07-2026 04:00
Alvotech further strengthens liquidity by securing term loan facility of $75 million

DISCLAIMER: The stock market data provided on this website is for informational purposes only and is not intended for trading purposes. While we strive to provide accurate and timely information, we cannot guarantee that the information is accurate at the moment it is received or that it will continue to be accurate in the future. We are not responsible for any actions taken based on the information provided on this website. Always consult with a licensed financial professional before making any investment decisions.
Terms of Service

Copyright © 2025 MarketSnap. All rights reserved.

Contact Us

Privacy Policy

Cookie Policy

Terms of Service

Hover Image
MARKETSnap

Market

🇺🇸 United States

Language

    • Gainers & Losers
    • Most Active & More
    • 52-Week High/Low
    • Dividends
      • Large Caps
      • Absolute
      • Total Market PE
      • Large Caps
      • Absolute
      • Industry
      • Sector
  • 💰 Stock intrinsic value Calculator
  • 📈 Investment Compounding Calculator
  • 🤖 Stock Pick Screener
  • 📋 Watchlist & Portfolio
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
    • Commodities
    • Currencies
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
  • Philosophy
  • Nexus
  • Login Login
  • Profile Profile
  • Watchlist & Portfolio Watchlist & Portfolio
  • My Valuations My Valuations
  • Settings Settings

Media

Watch Listen Read